MEDICO REMEDIES LTD.
A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE
Manufacturers of Pharmaceutical Formulations
CIN : L24230MH1994PLC077187
GSTIN- 27AABCM8349L1ZY.
Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com • info@medicoremedies.com • Website : www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

Date: 9th November, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 **Scrip Code: 540937**	**National Stock Exchange of India Limited** 5th Floor, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai-400051 **Symbol: MEDICO**

Dear Sir/Madam,

Re.: Outcome of Board Meeting held today

Sub: Intimation under Regulation 30 (read with Part A of Schedule III) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 9th November, 2026 has, inter alia considered and approved the following:

1. Unaudited Standalone Financial Results for the quarter ended 30th September 2026 alongwith Auditors' Limited Review Report thereon;
2. Appointment of M/s V. J. Talati & Co. as the Cost Auditors of the Company for the financial year ending 31st March, 2027; and
3. Postal Ballot Notice

The requisite disclosure, pursuant to Para A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as **Annexure 'A'.**

We wish to inform you that the Board Meeting commenced today at 4:30 P.M. and concluded at 5:15 P.M.

Kindly take the same on record.

Thanking you,

FOR MEDICO REMEDIES LIMITED

HARESH KAPURLAL MEHTA
Digitally signed by HARESH KAPURLAL MEHTA
Date: 2026.11.09 17:09:45 +05'30'

HARESH MEHTA
CHAIRMAN & WHOLE-TIME DIRECTOR
DIN: 01080289
Encl: As above

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com • info@medicoremedies.com • **Website :** www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

Annexure-A

Disclosure pursuant to Para A of Part A of Schedule Ill of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024

Appointment of Cost Auditor

Sr. No	Particulars	Disclosure
1	Reason of change viz appointment, ~~resignation, removal, death or otherwise~~	Appointment of Cost Auditor for FY 2026-27
2	Date of Appointment & Term of appointment	Appointment approved in the Board meeting held on 9th November 2026 as Cost Auditor for FY 2026-27 to issue Cost Audit Report as per the provisions of the Companies Act, 2013
3	Brief Profile	M/s. V. J. Talati & Co., Cost Accountants, Mumbai (Firm Regd. No. R00213) has experience and expertise in Cost Audit over the years. The firm also provides Guidance for Maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014 and certification as regards maintenance of Cost Records by the Company.

Shah Shroff & Associates

Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Medico Remedies Limited pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended

To

THE BOARD OF DIRECTORS

MEDICO REMEDIES LIMITED

1105/1106, 11th Floor, Hubtown Solaris

Opp. Telli Galli, N S Phadke Marg,

Andheri East, Mumbai - 400069

Dear Sirs,

Re: Limited Review Report of the Unaudited Standalone Financial Results for the quarter and half year ended 30th September, 2026

We have reviewed the accompanying Statement of unaudited Standalone Financial Results of Medico Remedies Limited ("the Company") comprising of profit and loss account, statement of assets and liabilities and statement of cash flow for the half year ended 30th September, 2026, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 ('the Regulation') as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management has been reviewed by Audit Committee and approved by the Board of Directors at their respective meetings held on 09th November, 2026 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (IND AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Shah Shroff & Associates ★ MUMBAI FRN 128920W ★ Chartered Accountants

A703, Winsway Complex, Old Police Lane, Andheri (E), Mumbai - 400 069.
Tel.: +91-22 - 6127 7488 / 6697 3268 Email : shahshroff@gmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standard specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shah Shroff & Associates

Chartered Accountants

Firm Registration No.: 128920W



Yashesh Shroff

Partner

Membership Number – 103277

UDIN: 25103277TIHGDT6791

Place: Mumbai

Date: 09.11.2026

MEDICO REMEDIES LIMITED

CIN: L24230MH1994PLC077187

Statement of Unaudited Standalone Financial Results for the quarter and half year ended on September 30, 2026

(Rs. In lakhs)

Sn	Particulars	Quarter ended			Half year ended		For the Year Ended
		30-Sep-26 (Unaudited)	30-Jun-26 (Unaudited)	30-Sep-25 (Unaudited)	30-Sep-26 (Unaudited)	30-Sep-25 (Unaudited)	31-Mar-26 (Audited)
1	**INCOME**						
	(a) Revenue from Operations	7,397.20	6,940.06	5,263.52	14,337.26	9,088.67	20,637.73
	(b) Other Income	130.61	116.86	172.48	247.47	238.29	593.35
	Total Income (a+b)	**7,527.81**	**7,056.92**	**5,436.00**	**14,584.73**	**9,326.96**	**21,231.08**
2	**Expenses**						
	(a) Cost of raw materials consumed	6,581.99	4,719.53	4,334.92	11,301.52	7,205.83	14,858.71
	(b) Purchase of traded goods	60.30	120.42	111.79	180.72	174.25	441.32
	(c) Changes in inventories of finished goods. work-in progress and traded goods	(538.94)	735.86	(402.28)	196.92	(601.79)	(167.27)
	(d) Employee Benefits Expense	194.04	195.76	181.00	389.79	351.36	739.82
	(e) Finance Costs	44.88	40.62	23.51	85.50	51.62	180.63
	(f) Depreciation and Amortisation Expense	75.29	72.34	73.36	147.63	150.26	309.46
	(g) Other Expenses	783.22	838.44	766.28	1,621.66	1,404.61	3,062.45
	Total expenses	**7,200.77**	**6,722.97**	**5,088.58**	**13,923.74**	**8,736.14**	**19,425.12**
3	**Profit/(Loss) before Tax (1-2)**	**327.04**	**333.95**	**347.42**	**661.00**	**590.82**	**1,805.96**
4	**Income Tax expenses**						
	a) Current Tax	79.00	71.00	77.42	150.00	131.00	505.55
	b) Deferred Tax [(charge/(credit)]	10.16	11.16	13.17	21.32	21.18	(11.11)
	Total Tax Expenses	**89.16**	**82.16**	**90.59**	**171.32**	**152.18**	**494.44**
5	**Profit/(Loss) for the period (3-4)**	**237.88**	**251.80**	**256.83**	**489.68**	**438.64**	**1,311.52**
6	Other comprehensive income not to be reclassified to Profit and Loss in subsequent periods						
	Profit and Loss in subsequent periods						
	Re-measurement gain/(losses) on defined benefit Plans	(3.70)	(3.70)	0.16	(7.40)	0.32	(14.65)
	Tax effect [(charge)/credit]	0.93	0.93	(0.04)	1.86	(0.08)	3.69
	Other comprehensive income/(loss) (net of tax)	**(2.77)**	**(2.77)**	**0.12**	**(5.54)**	**0.24**	**(10.96)**
7	Total comprehensive income/(loss) for the period (5+6)	**235.12**	**249.03**	**256.95**	**484.14**	**438.88**	**1,300.56**
8	Paid-up equity share capital(Face value per share: Re.2/-)	1,659.68	1,659.68	1,659.68	1,659.68	1,659.68	1,659.68
9	Other Equity excluding revaluation reserve as per the audited balance sheet						5,887.77
10	Earning per Equity Share of face value of Re.2/- each (Not Annualised)						
	Basic EPS (in Rs.)	**0.29**	**0.30**	**0.31**	**0.59**	**0.53**	**1.58**
	Diluted EPS (in Rs.)	**0.29**	**0.30**	**0.31**	**0.59**	**0.53**	**1.58**

For Medico Remedies Limited

Haresh Mehta
Chairman and Whole Time Director
DIN: 01080289

MEDICO REMEDIES LTD. MUMBAI

For Medico Remedies Limited

Harshit Mehta
Managing Director
DIN: 05144280

Medico Remedies Limited

(CIN - L24230MH1994PLC077187)

Unaudited Standalone Statement of Assets and Liabilities

(Rs. In lakhs)

Particulars	As at 30 September, 2026 Unaudited	As at 31 March, 2026 Audited
I Assets		
Non-Current Assets		
(a) Property, plant and equipment	1,964.70	2,009.89
(b) Right of use asset	6.92	27.69
(c) Capital work in progress	406.33	257.33
(d) Intangible assets	2.81	3.64
(e) Financial assets	-	-
(i) Investments	3.70	4.30
(iii) Other financial assets	94.71	84.07
(f) Deferred tax assets (net)	20.09	39.54
(g) Other non-current assets	28.51	22.12
Total Non current Assets	**2,527.77**	**2,448.57**
Current Assets		
(a) Inventories	3,417.08	3,001.58
(b) Financial assets		
(i) Investments	189.60	184.43
(ii) Trade receivables	12,020.43	8,199.24
(iii) Cash and cash equivalents	356.74	190.69
(iv) Other financial assets	28.82	28.77
(c) Other current assets	1,663.69	1,287.06
Total Current Assets	**17,676.37**	**12,891.76**
Total Assets	**20,204.14**	**15,340.33**
II Equity and Liabilities		
1 **Equity**		
(a) Equity share capital	1,659.68	1,659.68
(b) Other equity	6,371.91	5,887.77
Total Equity	**8,031.59**	**7,547.45**
Liabilities		
2 **Non-Current Liabilities**		
(a) Financial liabilities		
(i) Borrowings	459.33	28.63
(ii) Trade payables		
- dues of micro and small enterprises	-	-
- dues of other creditors	-	-
Total Non current liabilities	**459.33**	**28.63**
3 **Current Liabilities**		
(a) Financial liabilities		
(i) Borrowings	2,770.52	1,854.90
(ii) Trade payables		
- dues of micro and small enterprises	801.98	221.40
- dues of other creditors	7,461.80	4,711.43
(iii) Other financial liabilities	46.13	44.33
(b) Provisions	-	275.46
(c) Other current liabilities	632.80	656.73
Total Current Liabilities	**11,713.22**	**7,764.26**
Total Equity and Liabilities	**20,204.14**	**15,340.33**

For Medico Remedies Limited

Haresh Mehta
Chairman and Whole Time Director
DIN: 01080289

MEDICO REMEDIES LTD. MUMBAI

For Medico Remedies Limited

Harshit Mehta
Managing Director
DIN: 05144280

Medico Remedies Limited
(CIN - L24230MH1994PLC077187)
Unaudited Standalone Statement of Cash Flows for the half year ended 30th September, 2026

Particulars	Half year ended September 30, 2026	Half year ended September 30, 2025
	Unaudited	Unaudited
CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax	**661.00**	**590.81**
Adjustment to reconcile profit before tax to net cash flows		
Depreciation	147.63	150.26
Gratuity expenses routed through OCI	(7.40)	0.32
(Gain) / Loss on Disposal of Property, Plant and Equipment	-	(0.82)
Interest on Lease	1.02	3.07
Interest (income)	(6.78)	(6.77)
Provision for expected credit losses and doubtful advances	21.03	(1.76)
Operating profit before working capital changes	**816.50**	**735.11**
Movements in working capital:		
Increase/ (decrease) in trade payables	3,330.94	1,889.29
Increase/ (decrease) in provisions	(275.46)	-
(Decrease)/Increase in Others (Current and Non-Current Liabilities)	(23.93)	(355.15)
Increase/ (decrease) in other financial liabilities	29.27	-
Decrease / (increase) in trade receivables	(3,842.23)	(17.69)
(Decrease)/Increase in Borrowing	1,346.32	(193.32)
Decrease / (increase) in inventories	(415.51)	(1,465.55)
Decrease / (increase) in others financial assets	(0.05)	(15.52)
Decrease / (increase) in others current assets	(383.01)	(387.87)
Cash generated from / (used in) operations	**582.84**	**189.30**
Income tax paid (net of refund)	**(150.00)**	**(131.00)**
Net cash flow from/ (used in) operating activities (a)	**432.84**	**58.30**
CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase of fixed assets including CWIP and capital advances	(229.86)	(122.88)
Proceeds on sale of Property, Plant and Equipments	-	6.50
Investments (Net)	(5.17)	(4.47)
Interest (income)	6.78	6.77
Loans/Deposits advanced to parties	(10.65)	-
Changes in Plan Assets / Effect of OCI	0.60	-
Net cash flow from/ (used in) investing activities (b)	**(238.29)**	**(114.08)**
CASH FLOW FROM FINANCING ACTIVITIES :		
Payment of lease liabilities	(28.50)	(27.00)
Net cash flow from/ (used in) financing activities (c)	**(28.50)**	**(27.00)**
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (a+b+c)	**166.05**	**(82.79)**
Cash and cash equivalents at the beginning of the year		
Cash on hand	10.33	14.28
Bank Balance	180.36	95.21
	190.69	**109.49**
Cash and cash equivalents at the end of the year		
Cash on hand	6.81	13.40
Bank Balance	349.93	13.30
	356.74	**26.70**

Notes :

1. The statement of cash flows has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) statement of Cash Flows

For Medico Remedies Limited

Haresh Mehta
Chairman and Whole Time Director
DIN: 01080289

MEDICO REMEDIES LTD. MUMBAI

For Medico Remedies Limited

Harshit Mehta
Managing Director
DIN: 05144280

Notes:

1. The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on November 09, 2026 and subsequently approved by the Board of Directors at its meeting held on November 09, 2026. The review report has been filed with stock exchange and is available on the Company's website.

2. The figures for the quarter ended on 30th September 2026 are balancing figures between the review figures for the quarter ended 30th June 2026 and reviewed year to date figures upto six month ended 30th September 2026.

3. The standalone financial results for the quarter ended on 30th September, 2026 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results.

4. The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company.

5. Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 "Operating Segments" notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below:

PARTICULARS		QE 30.09.2026	QE 30.06.2026
		Amount (Rs. In Lakh)	Amount (Rs. In Lakh)
1)	Sales of products within India	3845.90	2633.62
2)	Sales of products Outside India	3532.97	4269.74
	Sub- Total	**7378.87**	**6903.36**

6. Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods.

7. The company does not have any subsidiary/associate/joint venture company as on 30th September 2026.

8. The result for the quarter ended September 30, 2026 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.medicoremedies.com)

For and on behalf of the board,
For Medico Remedies Limited

Haresh Mehta
Chairman and Whole Time Director
DIN:01080289
Place: Mumbai
Date: November 09, 2026

MEDICO REMEDIES LTD. MUMBAI

Harshit Mehta
Managing Director
DIN:05144280
Place: Mumbai
Date: November 09, 2026